Nerve agents are perhaps the most feared of potential agents of chemical attack. The authors review the history, physical characteristics, pharmacology, clinical effects, and treatment of these agents.
Get full access to this article
View all access options for this article.
References
1.
1. Sidell FR, Borak J. Chemical warfare agents: II. Nerve agents . Ann Emerg Med. 1992;21: 865-871 .
2.
2. Shemer J, Danon YL. Eighty years of the threat and use of chemical warfare: the medical-organizational challenge . Israel J Med Sci. 1991;27: 608-612 .
3.
3. Somani SM, Solana RP, Dube SN. Toxicodynamics of nerve agents. In: Somani SM, ed. Chemical Warfare Agents. San Diego: Academic Press ; 1992:67-123.
4.
4. Oliver A, Arnett P. Did the U.S. drop nerve gas? Time. 1998;37-40.
5.
5. Siemaszko C. Vets: U.S. used nerve gas, say war defectors were targets. New York Daily News. 1998:5-5.
6.
6. Sidell FR. Nerve agents. In: Sidell FR, Takafuji TE, Franz DR, eds. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Falls Church, VA: Office of the Surgeon General, U.S. Army ; 1997:129-179.
18. Gallo MA, Lawryk NJ. Organic phosphorus pesticides. In: Hayes WJ, Laws ER Jr, eds. Handbook of Pesticide Toxicology. Chestnut Hill, MA: Academic Press ; 1991:917-972.
19.
19. Sullivan JB, Blose J. Organophosphate and carbamate insecticides. In: Sullivan JB, Krieger GR, eds. Hazardous Materials Toxicology-Clinical Principles of Environmental Health. Baltimore: Williams & Wilkins ; 1992:1015-1026.
20.
20. Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics (10th ed.). New York: McGraw-Hill ; 2001:175-191.
21.
21. Saxena A, Doctor BP, Maxwell DM, et al. The role of glutamate-199 in the aging of cholinesterase . Biochem Biophys Res Comm. 1993;197: 343-349 .
22.
22. Curry SC, Mills KC, Graeme KA. Neurotransmitters. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al. Goldfrank’s Toxicologic Emergencies (7th ed.). New York: McGraw-Hill ; 2002:133-165.
23.
23. Hoffman RS, Henry GC, Howland MA, et al. Association between life-threatening cocaine toxicity and plasma cholinesterase activity . Ann Emerg Med. 1992;21: 247-253 .
24.
24. Cerf C, Mesguish M, Gabriel I, et al. Screening patients with prolonged neuromuscular blockade after succinylcholine and mivacurium . Anesth Analg. 2002;94: 461-466 .
25.
25. Fonnum F, Sterri SH. Factors modifying the toxicity of organophosphorous compounds including Soman and Sarin . Fund Appl Toxicol. 1981;1: 143-147 .
26.
26. Karczmar AG. Present and future development of anti-OP drugs . Fund Appl Toxicol. 1985;5: S270-S279 .
27.
27. El-Etri MM, Nickell WT, Ennis M, et al. Brain norepinephrine reductions in Soman-intoxicated rats: association with convulsions and AChE inhibition, time course, and relation to other monoamines . Exp Neurol. 1992;118: 153-163 .
28.
28. El-Etri MM, Ennis M, Jiang M, Shipley MT. Pilocarpineinduced convulsions in rats: evidence for muscarinic receptor-mediated activation of locus ceruleus and norepinephrine release in cholinolytic seizure development . Exp Neurol. 1993;121: 24-39 .
29.
29. Lallement G, Carpentier P, Pernot-Marino I, et al. Transient impairment of the gabaergic function during initiation of Soman-induced seizures . Brain Res. 1993;629: 239-244 .
30.
30. Braitman DJ, Sparenborg S. MK-801 protects against seizures induced by the cholinesterase inhibitor Soman . Brain Res Bull. 1989;23: 145-148 .
31.
31. Petras JM. Soman neurotoxicity . Fund Appl Toxicol. 1981;1: 242-242 .
32.
32. Sidell FR. Soman and Sarin: clinical manifestations and treatment of accidental poisoning by organophosphates . Clin Toxicol. 1974;7: 1-17 .
33.
33. Sidell FR, Groff WA. The reactivatibility of cholinesterase inhibited by VX and Sarin in man . Toxicol Appl Pharmacol. 1974;27: 241-252 .
34.
34. Craig FN, Cummings EG, Sim VM. Environmental temperature and the percutaneous absorption of a cholinesterase inhibitor, VX . J Invest Dermatol. 1977;68: 357-361 .
35.
35. Oberst FW, Koon WS, Christensen MK, et al. Retention of inhaled Sarin vapor and its effect on red blood cell cholinesterase activity in man . Clin Pharmacol Ther. 1968;9: 421-427 .
36.
36. Nozaki H, Aikawa N, Shinozawa Y, et al. Sarin poisoning in Tokyo subway (letter) . Lancet. 1995;345: 980-981 .
37.
37. Kluwe WM, Chinn JC, Feder P, et al. Efficacy of Pyridostigmine pretreatment against acute Soman intoxication in a primate model. In: Proceedings of the Sixth Medical Chemical Defense Bioscience Review. Aberdeen Proving Ground, MD: U.S. Army Research Institute for Chemical Defense ; 1987:227-234. Report ADB121516.
38.
38. Bird SB, Gaspari RJ, Lee WJ, Dickson EW. Diphenhydramine as a protective agent in a rat model of acute, lethal organophosphate poisoning . Acad Emerg Med. 2002;9: 1369-1372 .
39.
39. Wright PG. An analysis of the central and peripheral components of respiratory failure produced by anti- cholinesterase poisoning in the rabbit . J Physiol. 1954;126: 52-70 .
40.
40. Rickett DL, Glenn JF, Beers ET. Central respiratory effects versus neuromuscular actions of nerve agents . Neurotoxicology. 1986;7: 225-236 .
41.
41. Stewart WC, Anderson EA. Effect of a cholinesterase inhibitor when injected into the medulla of the rabbit . J Pharmacol Exp Ther. 1968;162: 309-318 .
42.
42. Bird SB, Gaspari RJ, Dickson EW. Early death due to severe organophosphate poisoning is a centrally mediated process . Acad Emerg Med. 2003;10: 295-298 .
43.
43. Bowers MB, Goodman E, Sim VM. Some behavioral changes in man following anticholinesterase administration . J Neurol Ment Disord. 1964;138: 383-389 .
44.
44. Hatta K, Miura Y, Asukai N, Hamabe Y. Amnesia from Sarin poisoning (letter) . Lancet. 1996;347: 1343-1343 .
45.
45. Senanayake N, de Silva HJ, Karalliedde L. A scale to assess severity in organophosphorous intoxication: POP scale . Hum Exp Toxicol. 1993;12: 297-299 .
46.
46. Yokoyama K, Yamada A, Mimura N, et al. Clinical profiles with Sarin poisoning after the Tokyo subway attack (letter) . Am J Med. 1996;100: 586-586 .
47.
47. Dressel TD, Goodale RL Jr, Arneson MA, Borner JW. Pancreatitis as a complication of anticholinesterase insecticide intoxication . Ann Surg. 1979;189: 199-204 .
48.
48. Lee WC, Yang CC, Deng JF, et al. The clinical significance of hyperamylasemia in organophosphate poisoning . Clin Toxicol. 1998;36: 673-681 .
49.
49. Dagli AJ, Shaikh WA. Pancreatic involvement in malathionanticholinesterase insecticide intoxication a study of 75 cases . Br J Clin Pract. 1983;37: 270-272 .
50.
50. Brill DM, Maisel AS, Prabhu R. Polymorphic ventricular tachycardia and other complex arrhythmias in organophosphate insecticide poisoning . J Electrocardiography. 1984;17: 97-102 .
51.
51. Clark RF. Insecticides: organic phosphorus compounds and carbamates. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al. Goldfrank’s Toxicologic Emergencies (7th ed). New York: McGraw-Hill ; 2002:1346-1360.
52.
52. Bajgar J. Biological monitoring of exposure to nerve agents . Br J Indust Med. 1992;49: 648-653 .
53.
53. Polhuijs M, Langenberg JP, Benschop HP. New method for retrospective detection of exposure to organophosphorous anticholinesterases: application to alleged Sarin victims of Japanese terrorists . Toxicol Appl Pharmacol. 1997;146: 156-161 .
54.
54. Nagao M, Takatori T, Matsuda Y, et al. Definitive evidence for the acute Sarin poisoning diagnosis in the Tokyo subway . Toxicol Appl Pharmacol. 1997;144: 198-203 .
55.
55. Tsuchihashi H, Munehiro K, Nishikawa M, Tatsuno M. Identification of metabolites of nerve agent VX in serum collected from a victim . J Analytic Toxicol. 1998;22: 383-388 .
56.
56. Okudera H, Morita H, Iwashita T, et al. Unexpected nerve gas exposure in the city of Matsumoto: report of rescue activity in the first Sarin gas terrorism . Am J Emerg Med. 1997;15: 527-528 .
57.
57. U.S. Army Medical Research Institute of Chemical Defense. Patient decontamination. In: Field Management of Chemical Casualties Handbook (2nd ed.). Aberdeen Proving Ground, MD: Chemical Casualty Care Division ; 2000:48-91.
58.
58. Knezevic DL, Tadic V, Cetkovic S. The efficacy of different decontaminants in rats and pigs percutaneously poisoned with organophosphates . Vet Human Toxicol. 1993;35: 403-405 .
59.
59. Koksal N, Buyukbese MA, Guven A, et al. Organophosphate intoxication as a consequence of mouth- to-mouth breathing from an affected case . Chest. 2002;122: 740-741 .
60.
60. Dunn MA, Sidell FR. Progress in medical defense against nerve agents . JAMA. 1989;262: 649-652 .
61.
61. Shockley LW. The use of nebulized atropine for the treatment of malathion poisoning . J Tox Clin Tox. 1989;27: 183-192 .
62.
62. Sidell FR, Markis JE, Groff W, Kaminskis A. Enhancement of drug absorption after administration by an automatic injector . J Pharmacokinet Biopharmaceut. 1974;2: 197-210 .
63.
63. Friedl KE, Hannan CJ Jr, Schadler PW, Jacob WH. Atropine absorption after intramuscular administration with 2- pralidoxime chloride by two automatic injector devices . J Pharm Sci. 1989;78: 728-731 .
64.
64. Nyberg AG, Cassel G, Jeneskog T, et al. Pharmacokinetics of HI-6 and atropine in anaesthetized pigs after administration by a new autoinjector . Biopharmaceut Drug Disp. 1995;16: 635-651 .
65.
65. Suchard JR. Chemical and biological weapons. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al. Goldfrank’s Toxicologic Emergencies (7th ed). New York: McGraw-Hill ; 2002:1527-1551.
67. Howland MA. Antidotes in depth: pralidoxime. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al., eds. Goldfrank’s Toxicologic Emergencies (7th ed). New York: McGraw-Hill ; 2002:1361-1365.
68.
68. Murtha EF, Fleisher JH, Torre MA, Innerebner TA. Reactivatability of Soman-inhibited end plate cholinesterase and neuromuscular transmission . Toxicol Appl Pharmacol. 1970;16: 214-226 .
69.
69. Lundy PM, Hansen AS, Hand BT, Boulet CA. Comparison of several oximes against poisoning by Soman, Tabun, and GF . Toxicology. 1992;72: 99-105 .
70.
70. Inns RH, Leadbeater L. The efficacy of bispyridinium derivatives in the treatment of organophosphate poisoning in the guinea pig . J Pharm Pharmacol. 1983;35: 427-433 .
71.
71. Zvirblis P, Kondritzer AA. Prophylaxis against sarin poisoning in the rat by oral administration of pralidoxime chloride . J Pharmacol Exp Ther. 1967;157: 432-434 .
72.
72. Sundwall A. Minimum concentrations of N-methylpyridinium- 2-aldoxime methane sulphonate (P2S) which reverses neuromuscular block . Biochem Pharmacol. 1961;8: 413-417 .
73.
73. Worek F, Bäcker M, Thiermann H, et al. Reappraisal of indications and limitations of oxime therapy in organophosphate poisoning . Hum Exp Toxicol. 1997; 16: 466-472 .
74.
74. Dawson A, Buckley N, Whyte I. What target pralidoxime concentration? (letter) . Clin Toxicol. 1997;35: 227-228 .
76. Medicis JJ, Stork CM, Howland MA, et al. Pharmacokinetics following a loading plus a continuous infusion of pralidoxime compared with the traditional short infusion regimen in human volunteers . Clin Toxicol. 1996;34: 289-295 .
77.
77. Singh S, Chaudhry D, Behera D, et al. Aggressive atropinization and continuous pralidoxime (2-PAM) infusion in patients with severe organophosphate poisoning: experience of a northwest Indian hospital . Hum Exp Toxicol. 2001;20: 15-18 .
78.
78. Boskovic B. The treatment of Soman poisoning and its perspectives . Fundam Appl Toxicol. 1981;1: 203-213 .
79.
79. Murphy MR, Blick DW, Dunn MA, et al. Diazepam as a treatment for nerve agent poisoning in primates . Aviat Space Environ Med. 1993;64: 110-115 .
80.
80. Dawson RM. Review of oximes available for treatment of nerve agent poisoning . J Appl Toxicol. 1994;14: 317-331 .
81.
81. Gilat E, Goldman M, Lahat E, et al. Nasal midazolam as a novel anticonvulsive treatment against organophosphateinduced seizure activity in the guinea pig . Arch Toxicol. 2003;77: 167-172 .
82.
82. Henretig FM, Crawford M, Jew R. Potential use of autoinjectorpackaged antidotes for treatment of pediatric nerve agent toxicity . Ann Emerg Med. 2002;40: 405-408 .
83.
83. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people . J R Soc Med. 2000;93: 457-462 .
84.
84. Okumura T. Organophosphate poisoning in pregnancy . Ann Emerg Med. 1997;29: 299-299 .
85.
85. Morgan JP. The Jamaica ginger paralysis . JAMA. 1982;248: 1864-1867 .
86.
86. Lotti M, Moretto A, Zoppellari R, et al. Inhibition of lymphocytic neuropathy target esterase predicts the development of organophosphate-induced delayed neuropathy . Arch Toxicol. 1986;59: 176-179 .
87.
87. Johnson MK. Symposium introduction: retrospect and prospects for neuropathy target esterase (NTE) and the delayed polyneuropathy (OPIDP) induced by some organophosphorous esters . Chem-Biol Int. 1993;87: 339-346 .
88.
88. Gordon JJ, Inns RH, Jonson MK, et al. The delayed neuropathic effects of nerve agents and some other organophosphorous compounds . Arch Toxicol. 1983;52: 71-82 .
89.
89. Funk KA, Liu CH, Higgins RJ, Wilson BW. Avian embryonic brain reaggregate culture system: II. NTE activity discriminates between effects of a single neuropathic or nonneuropathic organophosphorous compound exposure . Toxicol Appl Pharmacol. 1994;124: 159-163 .
90.
90. Senanayake N, Karalliedde L. Neurotoxic effects of organophosphate insecticides: an intermediate syndrome . N Engl J Med. 1987;316: 761-763 .
91.
91. De Bleecker J, Van Der Neucker K, Colardyn F. Intermediate syndrome in organophosphorous poisoning: a prospective study . Crit Care Med. 1993;21: 1706-1711 .
92.
92. De Bleecker J, Willems J, Van Der Neucker K, et al. Prolonged toxicity with intermediate syndrome after combined parathion and methyl parathion poisoning . Clin Toxicol. 1992;30: 333-345 .
93.
93. De Wilde V, Vogelaers D, Colardyn F, et al. Postsynaptic neuromuscular dysfunction in organophosphate induced intermediate syndrome . Klin Wochenschr. 1991;69: 177-183 .
94.
94. Jamal GA. Long term neurotoxic effects of organophosphate compounds . Adverse Drug React Toxicol Rev. 1995;14: 85-99 .
95.
95. Duffy FH, Burchfiel JL, Bartels PH, et al. Long-term effects of an organophosphate upon the human electroencephalogram . Toxicol Appl Pharmacol. 1979;47: 161-176 .
96.
96. Combs J, Hise L, Copeland R. High-pressure injection injury involving a 2-PAM chloride autoinjector . Military Med. 1992;157: 434-436 .
97.
97. Amitai Y, Almog S, Singer R, et al. Atropine poisoning in children during the Persian Gulf crisis: a national survey in Israel . JAMA. 1992;268: 630-632 .
98.
98. U.S. Army Medical Research Institute of Chemical Defense. Nerve Agents: GA, GB, GD, GF, VX. Medical Management of Chemical Casualties Handbook. 3rd ed. Aberdeen Proving Ground, MD: Chemical Casualty Care Division ; 2000:56-74.
99.
99. Geller RJ, Singleton KL, Tarantino ML. Nosocomial poisoning associated with emergency department treatment of organophosphate toxicity—Georgia, 2002 . MMWR. 2001;49: 1156-1157 .
100.
100. Deyi X, Lin Xiu W, Shuqiu P. The inhibition and protection of cholinesterase by physostigmine and pyridostigmine against soman poisoning in vivo . Fund Appl Toxicol. 1981;1: 217-221 .
101.
101. Dirnhuber P, French MC, Green DM, et al. The protection of primates against Soman poisoning by pretreatment with pyridostigmine . J Pharm Pharmacol. 1979;31: 295-299 .
102.
102. Keeler JR, Hurst CG, Dunn MA. Pyridostigmine used as a nerve agent pretreatment under wartime conditions . JAMA. 1991;266: 693-695 .
103.
103. Leadbeater L, Inns RH, Rylands JM. Treatment of poisoning by Soman . Fundam Appl Toxicol. 1985;5: S225-S231 .
104.
104. Wetters DC, Daniell WE, Treser CD. Hospital preparedness for victims of chemical or biological terrorism . Am J Public Health. 2001;91: 710-716 .
105.
105. Okumura T, Suzuki K, Fukuda A, et al. The Tokyo subway Sarin attack: disaster management, part 1: community emergency response . Acad Emerg Med. 1998;5: 613-617 .
106.
106. Okumura T, Suzuki K, Fukuda A, et al. The Tokyo subway Sarin attack: disaster management, part 2: hospital response . Acad Emerg Med. 1998;5: 618-624 .
107.
107. Okumura T, Suzuki K, Fukuda A, et al. The Tokyo subway Sarin attack: disaster management, part 3: national and international responses . Acad Emerg Med. 1998;5: 625-628 .
108.
108. Dunn MA, Hackley BE, Sidell FR. Pretreatment for nerve agent exposure. In: Sidell FR, Takafuji TE, Franz DR, eds. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Falls Church, VA: Office of the Surgeon General, U.S. Army ; 1997:181-196.
109.
109. Raveh L, Grauer E, Grunwald J, Cohen E, Ashani Y. The stoichiometry of protection against Soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase . Toxicol Appl Pharmacol. 1997;145: 43-53 .
110.
110. Ci YX, Zhou YX, Guo ZQ, et al. Production, characterization and application of monoclonal antibodies against the organophosphate nerve agent VX . Arch Toxicol. 1995;69: 565-567 .
111.
111. Cowan J, Sinton CM, Varley AW, et al. Gene therapy to prevent organophosphate intoxication . Toxicol Appl Pharmacol. 2001;173: 1-6 .
